Beta cell dysfunction as an acute and a post acute sequelae of COVID19

β 细胞功能障碍是 COVID19 的急性和急性后遗症

基本信息

  • 批准号:
    10505064
  • 负责人:
  • 金额:
    $ 58.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Beta cell dysfunction and death are significant pathologies underlying the development of Type 2 diabetes. Our long-term goal is to identify molecular mechanisms restrict beta cell function and survival. During the SARS- CoV2-driven COVID19 pandemic, there are reports of adult COVID19+ patients presenting with diabetic ketoacidosis in emergency rooms. 25% of new-onset type 1 diabetes (T1D) patients presenting with diabetic ketoacidosis in the T1D Exchange registry are COVID19+. Our group has reported a significant increase in the number of new-onset type 2 diabetes patients presenting in diabetic ketoacidosis. This suggests that the pathogenesis of COVID19 may have acute and specific effects on pancreatic beta cell function. One of the barriers to understanding how SARS-CoV2 infection may affect beta cell function and survival in patients is the limited number of physiologically relevant animal models to study. We have capitalized on unique access the pancreas of SCV2-innoculated animals to model and understand how the infection may affect beta cell function and survival. Our preliminary data that shows: (1) SARS-CoV2 directly infects beta cells, (2) SARS-CoV2 infection causes dramatic morphological changes in islet, (3) SARS-CoV2 infection shifts beta cell metabolism to glycolytic profile, and (4) SARS-CoV2 infection results in decreased in beta cell function and survival. The objective of this proposal is to define the mechanisms that drive the post-acute consequences of COVID19-mediated beta cell injury in vivo. There is controversy in the literature regarding if SARS-CoV2 directly infects beta cells and affects beta cell function and survival or if the disruption of glucose homeostasis in patients is secondary. We hypothesize that SARS-CoV2 infection reprograms cellular metabolism and induces necroptosis, thus leaving hosts susceptible to beta cell dysfunction acutely and as a post-acute sequelae of COVID19. These highly innovative experiments capitalize on a unique and clinically relevant model system and employs cutting edge techniques to assess how beta cell survival and metabolism are affected by SARS-CoV2 infection. These experiments will provide critical mechanistic insight to the underpinnings of the emerging clinical phenotype of acute hyperglycemia, diabetic ketoacidosis, and potentially lifelong diabetes that may afflict a significant number of patients who have recovered from COVID19.
项目摘要 β细胞功能障碍和死亡是2型糖尿病发展的重要病理。我们的 长期目标是确定分子机制限制了β细胞功能和存活。在sars- COV2驱动的COVID19大流行,有报道称成人Covid19+患有糖尿病的患者 急诊室中的酮症酸中毒。糖尿病患者的25%的1型糖尿病(T1D)患者 T1D交换注册中心中的酮症酸中毒为covid19+。我们的小组报告说 糖尿病性酮症酸中毒的2型糖尿病患者数量。这表明 COVID19的发病机理可能对胰腺β细胞功能具有急性和特异性作用。中的一个 了解SARS-COV2感染如何影响β细胞功能和患者的生存的障碍是 有限数量的生理相关动物模型。我们已经大写了独特的访问 SCV2启用动物的胰腺,以建模并了解感染如何影响β细胞功能 和生存。我们的初步数据显示:(1)SARS-COV2直接感染β细胞,(2)SARS-COV2 感染引起胰岛的急剧形态变化,(3)SARS-COV2感染转移β细胞代谢 糖酵解谱和(4)SARS-COV2感染导致β细胞功能和存活率降低。 该提议的目的是定义驱动急性后后果的机制 covid19介导的体内β细胞损伤。关于SARS-COV2的文献存在争议 直接感染β细胞并影响β细胞功能和存活,或者如果葡萄糖稳态破坏 患者是次要的。我们假设SARS-COV2感染重编程了细胞代谢和 诱导坏死性,因此使宿主易感β细胞功能障碍急性,并且是急性后 Covid19的后遗症。这些高度创新的实验利用了独特的临床相关模型 系统并采用尖端技术来评估β细胞存活和代谢如何受到 SARS-COV2感染。这些实验将为基础的基础提供关键的机械洞察力 急性高血糖,糖尿病性酮症酸中毒和潜在的终身糖尿病的新兴临床表型 可能会折磨大量从COVID19康复的患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Senta K Georgia其他文献

Senta K Georgia的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Senta K Georgia', 18)}}的其他基金

Mentoring Emerging Researchers at CHLA (MERCH-LA)
指导 CHLA (MERCH-LA) 的新兴研究人员
  • 批准号:
    10797938
  • 财政年份:
    2023
  • 资助金额:
    $ 58.48万
  • 项目类别:
Beta cell dysfunction as an acute and a post acute sequelae of COVID19
β 细胞功能障碍是 COVID19 的急性和急性后遗症
  • 批准号:
    10674887
  • 财政年份:
    2022
  • 资助金额:
    $ 58.48万
  • 项目类别:
Novel mechanisms to increase beta cell regeneration by p27
p27 促进 β 细胞再生的新机制
  • 批准号:
    8139830
  • 财政年份:
    2010
  • 资助金额:
    $ 58.48万
  • 项目类别:
Novel mechanisms to increase beta cell regeneration by p27
p27 促进 β 细胞再生的新机制
  • 批准号:
    7953261
  • 财政年份:
    2010
  • 资助金额:
    $ 58.48万
  • 项目类别:
Novel mechanisms to increase beta cell regeneration by p27
p27 促进 β 细胞再生的新机制
  • 批准号:
    8662377
  • 财政年份:
    2010
  • 资助金额:
    $ 58.48万
  • 项目类别:
Novel mechanisms to increase beta cell regeneration by p27
p27 促进 β 细胞再生的新机制
  • 批准号:
    8318235
  • 财政年份:
    2010
  • 资助金额:
    $ 58.48万
  • 项目类别:

相似海外基金

AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
艾滋病毒及相关感染治疗研究艾滋病临床试验小组
  • 批准号:
    10812944
  • 财政年份:
    2023
  • 资助金额:
    $ 58.48万
  • 项目类别:
Beta cell dysfunction as an acute and a post acute sequelae of COVID19
β 细胞功能障碍是 COVID19 的急性和急性后遗症
  • 批准号:
    10674887
  • 财政年份:
    2022
  • 资助金额:
    $ 58.48万
  • 项目类别:
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
领导和运营中心(LOC)、艾滋病临床试验组(ACTG);
  • 批准号:
    10594377
  • 财政年份:
    2022
  • 资助金额:
    $ 58.48万
  • 项目类别:
Increasing representation of black communities in SARS-CoV-2 serosurveys by understanding barriers and motivations for participation
通过了解参与的障碍和动机,增加黑人社区在 SARS-CoV-2 血清调查中的代表性
  • 批准号:
    10843497
  • 财政年份:
    2021
  • 资助金额:
    $ 58.48万
  • 项目类别:
A COVID-19 Pulmonary Outcome Clinical Prediction Rule Using Epigenetics
使用表观遗传学的 COVID-19 肺部结果临床预测规则
  • 批准号:
    10661384
  • 财政年份:
    2021
  • 资助金额:
    $ 58.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了